<VariationArchive VariationID="871093" VariationName="NM_000516.7(GNAS):c.348dup (p.Val117fs)" VariationType="Duplication" Accession="VCV000871093" Version="32" RecordType="classified" NumberOfSubmissions="6" NumberOfSubmitters="6" DateLastUpdated="2024-07-15" DateCreated="2020-05-12" MostRecentSubmission="2024-07-15">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="860659" VariationID="871093">
      <GeneList>
        <Gene Symbol="GNAS" FullName="GNAS complex locus" GeneID="2778" HGNC_ID="HGNC:4392" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>20q13.32</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="58839748" stop="58911192" display_start="58839748" display_stop="58911192" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="57414794" stop="57486249" display_start="57414794" display_stop="57486249" Strand="+" />
          </Location>
          <OMIM>139320</OMIM>
          <Haploinsufficiency last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GNAS">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GNAS">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000516.7(GNAS):c.348dup (p.Val117fs)</Name>
      <CanonicalSPDI>NC_000020.11:58903701:CCCCCC:CCCCCCC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>20q13.32</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="58903701" stop="58903702" display_start="58903701" display_stop="58903702" variantLength="1" positionVCF="58903701" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="57478756" stop="57478757" display_start="57478756" display_stop="57478757" variantLength="1" referenceAllele="C" alternateAllele="CC" positionVCF="57478756" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
      </Location>
      <ProteinChange>V58fs</ProteinChange>
      <ProteinChange>V102fs</ProteinChange>
      <ProteinChange>V760fs</ProteinChange>
      <ProteinChange>V103fs</ProteinChange>
      <ProteinChange>V117fs</ProteinChange>
      <ProteinChange>V118fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.10" sequenceAccession="NC_000020" sequenceVersion="10" change="g.57478762dup" Assembly="GRCh37">
            <Expression>NC_000020.10:g.57478762dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.11" sequenceAccession="NC_000020" sequenceVersion="11" change="g.58903707dup" Assembly="GRCh38">
            <Expression>NC_000020.11:g.58903707dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_016194.2" sequenceAccession="NG_016194" sequenceVersion="2" change="g.68968dup">
            <Expression>NG_016194.2:g.68968dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000516.7" sequenceAccession="NM_000516" sequenceVersion="7" change="c.348dup" MANESelect="true">
            <Expression>NM_000516.7:c.348dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000507.1" sequenceAccession="NP_000507" sequenceVersion="1" change="p.Val117fs">
            <Expression>NP_000507.1:p.Val117fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001077488.5" sequenceAccession="NM_001077488" sequenceVersion="5" change="c.351dup">
            <Expression>NM_001077488.5:c.351dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001070956.1" sequenceAccession="NP_001070956" sequenceVersion="1" change="p.Val118fs">
            <Expression>NP_001070956.1:p.Val118fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001077489.4" sequenceAccession="NM_001077489" sequenceVersion="4" change="c.303dup">
            <Expression>NM_001077489.4:c.303dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001070957.1" sequenceAccession="NP_001070957" sequenceVersion="1" change="p.Val102fs">
            <Expression>NP_001070957.1:p.Val102fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001077490.3" sequenceAccession="NM_001077490" sequenceVersion="3" change="c.*209dup">
            <Expression>NM_001077490.3:c.*209dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001309840.2" sequenceAccession="NM_001309840" sequenceVersion="2" change="c.171dup">
            <Expression>NM_001309840.2:c.171dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001296769.1" sequenceAccession="NP_001296769" sequenceVersion="1" change="p.Val58fs">
            <Expression>NP_001296769.1:p.Val58fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001309861.2" sequenceAccession="NM_001309861" sequenceVersion="2" change="c.171dup">
            <Expression>NM_001309861.2:c.171dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001296790.1" sequenceAccession="NP_001296790" sequenceVersion="1" change="p.Val58fs">
            <Expression>NP_001296790.1:p.Val58fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_016592.5" sequenceAccession="NM_016592" sequenceVersion="5" change="c.*254dup" MANEPlusClinical="true">
            <Expression>NM_016592.5:c.*254dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_080425.4" sequenceAccession="NM_080425" sequenceVersion="4" change="c.2277dup" MANEPlusClinical="true">
            <Expression>NM_080425.4:c.2277dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_536350.2" sequenceAccession="NP_536350" sequenceVersion="2" change="p.Val760fs">
            <Expression>NP_536350.2:p.Val760fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_080426.4" sequenceAccession="NM_080426" sequenceVersion="4" change="c.306dup">
            <Expression>NM_080426.4:c.306dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_536351.1" sequenceAccession="NP_536351" sequenceVersion="1" change="p.Val103fs">
            <Expression>NP_536351.1:p.Val103fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000516.4" sequenceAccession="NM_000516" sequenceVersion="4" change="c.348dup">
            <Expression>NM_000516.4:c.348dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2090848106" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000516.7(GNAS):c.348dup (p.Val117fs) AND not provided" Accession="RCV001090864" Version="25">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-05-23" SubmissionCount="4">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000516.7(GNAS):c.348dup (p.Val117fs) AND Pseudohypoparathyroidism type I A" Accession="RCV002250726" Version="3">
        <ClassifiedConditionList TraitSetID="66069">
          <ClassifiedCondition DB="MedGen" ID="C3494506">Pseudohypoparathyroidism type I A</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-05-22" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000516.7(GNAS):c.348dup (p.Val117fs) AND multiple conditions" Accession="RCV002489729" Version="2">
        <ClassifiedConditionList TraitSetID="69445">
          <ClassifiedCondition DB="MedGen" ID="C1857451">ACTH-independent macronodular adrenal hyperplasia 1</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0242292">McCune-Albright syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C4540135">Pituitary adenoma 3, multiple types</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0334041">Progressive osseous heteroplasia</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1864100">Pseudohypoparathyroidism type 1B</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C2932716">Pseudohypoparathyroidism type 1C</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3494506">Pseudohypoparathyroidism type I A</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0033835">Pseudopseudohypoparathyroidism</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-03-18" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-05-23" NumberOfSubmissions="6" NumberOfSubmitters="6" DateCreated="2020-05-12" MostRecentSubmission="2024-07-15">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11784876</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12621129</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23281139</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23796510</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25802881</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31886927</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="66069" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="56041" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Pseudohypoparathyroidism Type IA</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism type I A</ElementValue>
                <XRef ID="58833000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHP IA</ElementValue>
                <XRef Type="MIM" ID="103580" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pseudohypoparathyroidism type 1A</ElementValue>
                <XRef ID="Pseudohypoparathyroidism+type+1A/6035" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007078" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albright hereditary osteodystrophy with multiple hormone resistance</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1A</ElementValue>
                <XRef Type="MIM" ID="103580" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7486" />
                <XRef ID="7486" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79443" DB="Orphanet" />
              <XRef ID="C3494506" DB="MedGen" />
              <XRef ID="MONDO:0007078" DB="MONDO" />
              <XRef Type="MIM" ID="103580" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="69445" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3404" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">PHP IC</ElementValue>
                <XRef Type="MIM" ID="612462" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism type 1C</ElementValue>
                <XRef ID="Pseudohypoparathyroidism+type+1C/6037" DB="Genetic Alliance" />
                <XRef ID="MONDO:0012911" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PSEUDOHYPOPARATHYROIDISM, TYPE IC</ElementValue>
                <XRef Type="MIM" ID="612462" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0036" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0038" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0039" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0040" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1C</ElementValue>
                <XRef Type="MIM" ID="612462" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10681" />
                <XRef ID="10681" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79444" DB="Orphanet" />
              <XRef ID="C2932716" DB="MedGen" />
              <XRef ID="MONDO:0012911" DB="MONDO" />
              <XRef Type="MIM" ID="612462" DB="OMIM" />
            </Trait>
            <Trait ID="4057" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">PHP IB</ElementValue>
                <XRef Type="MIM" ID="603233" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism type 1B</ElementValue>
                <XRef ID="Pseudohypoparathyroidism+type+1B/6036" DB="Genetic Alliance" />
                <XRef ID="MONDO:0011301" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pseudohypoparathyroidism Type IB</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1B</ElementValue>
                <XRef Type="MIM" ID="603233" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10680" />
                <XRef ID="10680" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="94089" DB="Orphanet" />
              <XRef ID="C1864100" DB="MedGen" />
              <XRef ID="MONDO:0011301" DB="MONDO" />
              <XRef Type="MIM" ID="603233" DB="OMIM" />
            </Trait>
            <Trait ID="4060" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Pseudopseudohypoparathyroidism</ElementValue>
                <XRef ID="Pseudopseudohypoparathyroidism/6049" DB="Genetic Alliance" />
                <XRef ID="MONDO:0012912" DB="MONDO" />
                <XRef ID="237659007" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albright hereditary osteodystrophy without multiple hormone resistance</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PPHP</ElementValue>
                <XRef Type="MIM" ID="612463" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7860" />
                <XRef ID="7860" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79445" DB="Orphanet" />
              <XRef ID="C0033835" DB="MedGen" />
              <XRef ID="MONDO:0012912" DB="MONDO" />
              <XRef Type="MIM" ID="612463" DB="OMIM" />
            </Trait>
            <Trait ID="2828" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">McCune-Albright syndrome, somatic, mosaic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albright syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albright's Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">McCune-Albright syndrome</ElementValue>
                <XRef ID="McCune+Albright+syndrome/4524" DB="Genetic Alliance" />
                <XRef ID="MONDO:0018919" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albright's disease</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MAS</ElementValue>
                <XRef Type="MIM" ID="174800" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PFD</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">POFD</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Fibrous dysplasia / McCune-Albright syndrome (FD/MAS), the result of an early embryonic postzygotic somatic activating pathogenic variant in GNAS (encoding the cAMP pathway-associated G-protein, Gsα), is characterized by involvement of the skin, skeleton, and certain endocrine organs. However, because Gsα signaling is ubiquitous, additional tissues may be affected. Café au lait skin macules are common and are usually the first manifestation of the disease, apparent at or shortly after birth. Fibrous dysplasia (FD), which can involve any part and combination of the craniofacial, axial, and/or appendicular skeleton, can range from an isolated, asymptomatic monostotic lesion discovered incidentally to severe disabling polyostotic disease involving practically the entire skeleton and leading to progressive scoliosis, facial deformity, and loss of mobility, vision, and/or hearing. Endocrinopathies include: Gonadotropin-independent precocious puberty resulting from recurrent ovarian cysts in girls and autonomous testosterone production in boys; Testicular lesions with or without associated gonadotropin-independent precocious puberty; Thyroid lesions with or without non-autoimmune hyperthyroidism; Growth hormone excess; FGF23-mediated phosphate wasting with or without hypophosphatemia in association with fibrous dysplasia; and Neonatal hypercortisolism. The prognosis for individuals with FD/MAS is based on disease location and severity.</Attribute>
                <XRef ID="NBK274564" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6995" />
                <XRef ID="6995" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">25719192</ID>
                <ID Source="BookShelf">NBK274564</ID>
              </Citation>
              <Citation Type="review" Abbrev="Medical Genetics Summaries">
                <ID Source="BookShelf">NBK66130</ID>
              </Citation>
              <XRef ID="562" DB="Orphanet" />
              <XRef ID="C0242292" DB="MedGen" />
              <XRef ID="MONDO:0018919" DB="MONDO" />
              <XRef Type="MIM" ID="174800" DB="OMIM" />
            </Trait>
            <Trait ID="5691" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Osseus Heteroplasia, Progressive</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Progressive osseous heteroplasia</ElementValue>
                <XRef ID="Progressive+osseous+heteroplasia/5985" DB="Genetic Alliance" />
                <XRef ID="MONDO:0008153" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ECTOPIC OSSIFICATION, FAMILIAL</ElementValue>
                <XRef Type="MIM" ID="166350" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">POH</ElementValue>
                <XRef Type="MIM" ID="166350" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="109" />
                <XRef ID="109" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="2762" DB="Orphanet" />
              <XRef ID="C0334041" DB="MedGen" />
              <XRef ID="MONDO:0008153" DB="MONDO" />
              <XRef Type="MIM" ID="166350" DB="OMIM" />
              <XRef Type="primary" ID="HP:0025027" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="38135" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">PITUITARY ADENOMA 3, ACTH-SECRETING, SOMATIC</ElementValue>
                <XRef Type="Allelic variant" ID="139320.0012" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PITUITARY ADENOMA 3, GROWTH HORMONE-SECRETING, SOMATIC</ElementValue>
                <XRef Type="Allelic variant" ID="139320.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0009" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pituitary adenoma 3, multiple types</ElementValue>
                <XRef ID="MONDO:0054665" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PITA3</ElementValue>
                <XRef Type="MIM" ID="617686" DB="OMIM" />
              </Symbol>
              <XRef ID="C4540135" DB="MedGen" />
              <XRef ID="MONDO:0054665" DB="MONDO" />
              <XRef Type="MIM" ID="617686" DB="OMIM" />
            </Trait>
            <Trait ID="56005" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">CUSHING SYNDROME, ADRENAL, DUE TO AIMAH</ElementValue>
                <XRef Type="MIM" ID="219080" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA</ElementValue>
                <XRef Type="MIM" ID="219080" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CORTICOTROPIN-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA</ElementValue>
                <XRef Type="MIM" ID="219080" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ADRENOCORTICOTROPIC HORMONE-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA</ElementValue>
                <XRef Type="MIM" ID="219080" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">ACTH-independent macronodular adrenal hyperplasia 1</ElementValue>
                <XRef ID="MONDO:0020735" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ACTH-INDEPENDENT MACRONODULAR ADRENOCORTICAL HYPERPLASIA</ElementValue>
                <XRef Type="MIM" ID="219080" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ACTH-independent macronodular adrenal hyperplasia, somatic</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">AIMAH1</ElementValue>
                <XRef Type="MIM" ID="219080" DB="OMIM" />
              </Symbol>
              <XRef ID="C1857451" DB="MedGen" />
              <XRef ID="MONDO:0020735" DB="MONDO" />
              <XRef Type="MIM" ID="219080" DB="OMIM" />
            </Trait>
            <Trait ID="56041" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Pseudohypoparathyroidism Type IA</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism type I A</ElementValue>
                <XRef ID="58833000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHP IA</ElementValue>
                <XRef Type="MIM" ID="103580" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pseudohypoparathyroidism type 1A</ElementValue>
                <XRef ID="Pseudohypoparathyroidism+type+1A/6035" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007078" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albright hereditary osteodystrophy with multiple hormone resistance</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1A</ElementValue>
                <XRef Type="MIM" ID="103580" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7486" />
                <XRef ID="7486" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79443" DB="Orphanet" />
              <XRef ID="C3494506" DB="MedGen" />
              <XRef ID="MONDO:0007078" DB="MONDO" />
              <XRef Type="MIM" ID="103580" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4049674" SubmissionDate="2022-01-25" DateLastUpdated="2022-01-29" DateCreated="2022-01-29">
        <ClinVarSubmissionID localKey="NM_000516.5(GNAS):c.348dup|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002065894" DateUpdated="2022-01-29" DateCreated="2022-01-29" Type="SCV" Version="1" SubmitterName="Genetic Services Laboratory, University of Chicago" OrgID="1238" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>DNA sequence analysis of the GNAS gene demonstrated a single base pair duplication in exon 5, c.348dup. This duplication results in an amino acid frameshift and creates a premature stop codon 23 amino acids downstream of the change, p.Val117Argfs*23. This pathogenic sequence change is predicted to result in an abnormal transcript, which may be degraded, or may lead to the production of a truncated GNAS protein with potentially abnormal function. The c.348dup sequence change has not been described in population databases such as ExAC and gnomAD. This pathogenic sequence change has previously been described in individuals with GNAS-related disorders including three individuals with a diagnosis of pseudohypoparathyroidism 1A (confirmed de novo in two cases) and one individual with a diagnosis of progressive osseous heteroplasia (paternally inherited) (PMID: 12621129, 20689139, 117848760. This pathogenic sequence change is the most likely cause of this individual's phenotype, however functional studies have not been performed to prove this conclusively.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000516.5:c.348dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10987855</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4940064" SubmissionDate="2022-05-28" DateLastUpdated="2022-06-03" DateCreated="2022-06-03">
        <ClinVarSubmissionID localKey="20-57478756-G-GC" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002520970" DateUpdated="2022-06-03" DateCreated="2022-06-03" Type="SCV" Version="1" SubmitterName="3billion" OrgID="507830" OrganizationCategory="other" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The variant is not observed in the gnomAD v2.1.1 dataset. Frameshift: predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. The variant has been reported to be associated with GNAS related disorder (ClinVar ID: VCV000871093). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Proband>yes</Proband>
            </Sample>
            <Method>
              <NamePlatform>NovaSeq</NamePlatform>
              <TypePlatform>whole exome sequencing</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001513" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0000821" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0000843" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000516.7:c.348dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="103580" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11507599</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5434586" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_000516.7:c.348dup|OMIM:103580;166350;174800;219080;603233;612462;612463;617686" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002778605" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-03-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000516.7:c.348dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="103580" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="166350" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="174800" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="219080" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603233" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612462" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612463" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="617686" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7111242" SubmissionDate="2023-03-01" DateLastUpdated="2023-03-04" DateCreated="2023-03-04">
        <ClinVarSubmissionID localKey="GDXSV:260777" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV003805967" DateUpdated="2023-03-04" DateCreated="2023-03-04" Type="SCV" Version="1" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-08-26">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 31886927, 12621129)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <VariantType>Duplication</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:676720</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000516.4:c.348dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_166_20230301054205</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="6133062" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="4960653|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003443820" DateUpdated="2024-02-14" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12621129</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31886927</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11784876</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23281139</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23796510</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25802881</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 871093). This premature translational stop signal has been observed in individual(s) with clinical features of GNAS-related conditions (PMID: 12621129, 31886927). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Val117Argfs*23) in the GNAS gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GNAS are known to be pathogenic (PMID: 11784876, 23281139, 23796510, 25802881).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000020.10:g.57478756_57478757insC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2468223" SubmissionDate="2024-07-04" DateLastUpdated="2024-07-15" DateCreated="2020-05-12">
        <ClinVarSubmissionID localKey="101992|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001246624" DateUpdated="2024-07-15" DateCreated="2020-05-12" Type="SCV" Version="23" SubmitterName="CeGaT Center for Human Genetics Tuebingen" OrgID="505870" OrganizationCategory="laboratory" OrgAbbreviation="CHGT" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-04-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">CeGaT Center For Human Genetics Tuebingen Variant Classification Criteria Version 2</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/0ynenhfo/cegat_center_for_human_genetics_tuebingen_-_variant_classification_criteria_-_version_2.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="20" alternateAllele="CC" referenceAllele="C" start="57478762" stop="57478762" variantLength="1" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2021-07</SubmissionName>
          <SubmissionName>2021-10</SubmissionName>
          <SubmissionName>2022-01</SubmissionName>
          <SubmissionName>2022-01-corrected</SubmissionName>
          <SubmissionName>2022-04</SubmissionName>
          <SubmissionName>2022-07</SubmissionName>
          <SubmissionName>2022-08</SubmissionName>
          <SubmissionName>2022-10.3</SubmissionName>
          <SubmissionName>2023-01</SubmissionName>
          <SubmissionName>2023-04</SubmissionName>
          <SubmissionName>2023-09-add-ACMG-details</SubmissionName>
          <SubmissionName>2023-10</SubmissionName>
          <SubmissionName>2024-04</SubmissionName>
          <SubmissionName>SUB13641132</SubmissionName>
          <SubmissionName>SUB13985080</SubmissionName>
          <SubmissionName>SUB14102099</SubmissionName>
          <SubmissionName>SUB14290090</SubmissionName>
          <SubmissionName>SUB14426581</SubmissionName>
          <SubmissionName>SUB14513473</SubmissionName>
          <SubmissionName>SUB14584463</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5434586" TraitType="Disease" MappingType="XRef" MappingValue="174800" MappingRef="OMIM">
        <MedGen CUI="C0242292" Name="McCune-Albright syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5434586" TraitType="Disease" MappingType="XRef" MappingValue="617686" MappingRef="OMIM">
        <MedGen CUI="C4540135" Name="Pituitary adenoma 3, multiple types" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4940064" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001513" MappingRef="HP">
        <MedGen CUI="C0028754" Name="Obesity" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7111242" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5434586" TraitType="Disease" MappingType="XRef" MappingValue="166350" MappingRef="OMIM">
        <MedGen CUI="C0334041" Name="Progressive osseous heteroplasia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4940064" TraitType="Finding" MappingType="XRef" MappingValue="HP:0000821" MappingRef="HP">
        <MedGen CUI="C0020676" Name="Hypothyroidism" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5434586" TraitType="Disease" MappingType="XRef" MappingValue="612462" MappingRef="OMIM">
        <MedGen CUI="C2932716" Name="Pseudohypoparathyroidism type 1C" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4940064" TraitType="Finding" MappingType="XRef" MappingValue="HP:0000843" MappingRef="HP">
        <MedGen CUI="C0020502" Name="Hyperparathyroidism" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5434586" TraitType="Disease" MappingType="XRef" MappingValue="103580" MappingRef="OMIM">
        <MedGen CUI="C3494506" Name="Pseudohypoparathyroidism type I A" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="6133062" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5434586" TraitType="Disease" MappingType="XRef" MappingValue="603233" MappingRef="OMIM">
        <MedGen CUI="C1864100" Name="Pseudohypoparathyroidism type 1B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4049674" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4940064" TraitType="Disease" MappingType="XRef" MappingValue="103580" MappingRef="OMIM">
        <MedGen CUI="C3494506" Name="Pseudohypoparathyroidism type I A" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2468223" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5434586" TraitType="Disease" MappingType="XRef" MappingValue="612463" MappingRef="OMIM">
        <MedGen CUI="C0033835" Name="Pseudopseudohypoparathyroidism" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5434586" TraitType="Disease" MappingType="XRef" MappingValue="219080" MappingRef="OMIM">
        <MedGen CUI="C1857451" Name="ACTH-independent macronodular adrenal hyperplasia 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

